DRDO-Developed Drug '2-Deoxy-D-Glucose' Gets DCGI Approval for Emergency Use in Moderate to Severe COVID-19 Patients
The DCGI has granted permission for emergency use of therapeutic application of drug 2-deoxy-D-glucose (2-DG) as adjunct therapy in moderate to severe COVID-19 patients.
DRDO-Developed Drug '2-Deoxy-D-Glucose' Gets DCGI Approval for Emergency Use in Moderate to Severe COVID-19 Patients
The drug has been developed by DRDO lab Institute of Nuclear Medicine & Allied Sciences in collaboration with Dr Reddy’s Laboratories. Clinical trial have shown that this molecule helps in faster recovery of hospitalized patients & reduces supplemental oxygen dependence: DRDO
— ANI (@ANI) May 8, 2021
The drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production: DRDO
— ANI (@ANI) May 8, 2021
(The above story first appeared on LatestLY on May 08, 2021 01:40 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
